These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25486497)

  • 1. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
    Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
    Lin YL; Li YL; Ma JG
    Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
    Wang L; Xie PG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.
    Deng QK; Lei YG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2016 Feb; 22():516-21. PubMed ID: 26881880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of protocadherin8: Function as a tumor suppressor in hypopharyngeal carcinoma.
    Li Y; Liu C; Wang Z; Hu G
    Cancer Biomark; 2018; 22(3):495-502. PubMed ID: 29865037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
    Yang Y; Sun P; Xu W; Xia W
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
    Lin YL; Xie PG; Ma JG
    Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
    Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
    J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
    J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
    Stott-Miller M; Zhao S; Wright JL; Kolb S; Bibikova M; Klotzle B; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1331-9. PubMed ID: 24718283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
    Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
    Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.
    Lin YL; Deng QK; Wang YH; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2015 Dec; 21():3955-690. PubMed ID: 26683656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.